ArticleEuropean journal of nuclear medicine and molecular imaging2021
Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Contrast media & molecular imaging · 2022Pooled it
- Correlation of apparent diffusion coefficient, FAP expression in IHC and [EJNMMI research · 2026Article
- The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.Annals of nuclear medicine · 2026Review
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Differential [European journal of nuclear medicine and molecular imaging · 2026Article
- Is FAP the key to unlocking treatment for rare soft-tissue sarcomas?American journal of nuclear medicine and molecular imaging · 2026Article
- From bench to bedside, blade, and back: FAP expression in juvenile angiofibroma. Potential implications for FAPI-PET/CT imaging and targeted therapy?European journal of nuclear medicine and molecular imaging · 2026Article
- Current Position of Nuclear Medicine Imaging in Primary Bone Tumors.Diagnostics (Basel, Switzerland) · 2025Review
- Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review.Nuclear medicine and molecular imaging · 2025Review
- A fibroblast activation protein targeted optical tracer for identifying primary and metastatic sarcoma during resection.EJNMMI research · 2025Article
- The Role of Positron Emission Tomography Imaging in Primary Bone Tumours: A Narrative Review.Journal of clinical medicine · 2025Review
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- The diagnostic value of [European radiology · 2024Article
- FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review.Journal of biomedical physics & engineering · 2024Review
- From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Pigmented villonodular synovitis detected by [European journal of nuclear medicine and molecular imaging · 2024Article
- Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects.Annals of nuclear medicine · 2024Review
- Comparison ofDiagnostics (Basel, Switzerland) · 2023Article
- Translational assessment of a DATA-functionalized FAP inhibitor with facileEuropean journal of nuclear medicine and molecular imaging · 2023Article
- FAPI PET/CT Imaging-An Updated Review.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA high expression of fibroblast activation protein (FAP) was observed in multiple sarcomas, indicating an enormous potential for PET/CT using
methodsA cohort of 15 patients underwent
resultsExcellent tumor-to-background ratios (> 7) could be achieved due to low background activity and high SUVmax in primary tumors (median 7.16), local relapses (median 11.47), and metastases (median 6.29). The highest uptake was found for liposarcomas and high-grade disease (range 18.86-33.61). A high SUVmax (> 10) was observed for clinically more aggressive disease.
conclusionThese preliminary findings suggest a high potential for the clinical use of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.